MyFinsight
Home
Blog
About
Contact
Download
Download image
Total revenue
$517,145K
Gross profit
$362,532K
Other income, net
$10,424K
Canceled cashflow
$154,613K
Net income (loss)
$66,353K
Stock-based compensation
$43,601K
Depreciation and
amortization
$21,415K
Impairment loss
$20,505K
Canceled cashflow
$306,603K
Non-cash loss on
deconsolidation of subsidiary
-$6,708K
Accrued liabilities and
deferred revenue
$6,316K
Non-cash lease expense
$2,991K
Other assets
-$525K
Loss on disposal of
property, plant and...
-$15K
Cost of
revenue-Testing
$127,562K
Intangible asset
amortization - cost of revenue
$10,666K
Cost of
revenue-Product
$8,807K
Cost of
revenue-Biopharmaceutical And Other
$7,578K
Allocation of facilities
and it expenses
-$33,359K
Net cash provided by
operating activities
$136,307K
Canceled cashflow
$32,122K
General and
administrative
$110,784K
Selling and marketing
$100,165K
Research and development
$70,814K
Impairment of assets
$20,505K
Intangible asset
amortization - operating...
$2,487K
Income tax provision
(benefit)
$1,848K
Canceled cashflow
$33,359K
Laboratory supplies and
reagents expense
$57,284K
Compensation expense
$24,611K
Other cost
$19,655K
Allocation of facilities
and it expenses
$13,576K
Sample collection
expense
$12,436K
Product costs
$3,787K
Other cost
$3,348K
License fees and
royalties
$1,206K
Allocation of facilities
and it expenses
$466K
Other cost
$3,333K
Compensation expense
$3,320K
Allocation of facilities
and it expenses
$925K
Increase in cash, cash
equivalents and restricted...
$122,876K
Effect of foreign
currency on cash, cash...
$719K
Canceled cashflow
$13,431K
Revaluation of
acquisition-related contingent...
-$15,295K
Effect of foreign
currency on operations
$3,834K
Amortization of discount on
short-term investments
$3,270K
Supplies and inventory
$2,861K
Operating lease liability
-$2,480K
Prepaid expenses and
other current assets
$2,054K
Accounts payable
-$1,039K
Accounts receivable
$708K
Deferred income taxes
-$581K
Proceeds from maturity of
short-term investments
$153,311K
Proceeds from the
exercise of common stock...
$14,082K
Compensation expense
$82,909K
Other general and
administrative expenses
$61,234K
Compensation expense
$69,209K
Other selling and
marketing expenses
$14,943K
Allocation of facilities
and it expenses
$10,450K
Direct research and
development expense
$5,563K
Compensation expense
$37,784K
Direct research and
development expense
$16,596K
Other research and
development expenses
$8,492K
Allocation of facilities
and it expenses
$7,942K
Net increase in
cash, cash...
$123,595K
Net cash (used in)
provided by investing...
-$9,209K
Net cash (used in)
provided by financing...
-$4,222K
Canceled cashflow
$153,311K
Canceled cashflow
$14,082K
Purchase of short-term
investments
$149,998K
Payment of taxes on
vested restricted...
$18,304K
Purchases of property,
plant and equipment
$9,677K
Loss on
deconsolidation of subsidiary -...
$2,845K
Back
Back
Cash Flow
source: myfinsight.com
VERACYTE, INC. (VCYT)
VERACYTE, INC. (VCYT)